The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Primary analysis of TROPHY-U-01 cohort 3, a phase 2 study of sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based therapy.
 
Petros Grivas
Consulting or Advisory Role - 4D Pharma; Astellas Pharma; AstraZeneca; BostonGene; Bristol-Myers Squibb; Dyania Health; EMD Serono; Exelixis; Fresenius Kabi; G1 Therapeutics; Genentech; Gilead Sciences; Guardant Health; Infinity Pharmaceuticals; Janssen; Lucence; Merck; Mirati Therapeutics; Pfizer; PureTech; QED Therapeutics; Regeneron; Roche; Seagen; Silverback Therapeutics; Urogen pharma
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst)
 
Damien Pouessel
Honoraria - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Ipsen; Ipsen; Ipsen; Ipsen; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Merck; Merck; Merck; Merck
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Pfizer; Pfizer; Pfizer; Pfizer; Sanofi; Sanofi; Sanofi; Sanofi
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Merck Sharp and Dohme LLC, a subsidiary of Merck and Co., Inc, Rahway, NJ USA (Inst); Merck Sharp and Dohme LLC, a subsidiary of Merck and Co., Inc, Rahway, NJ USA (Inst); Merck Sharp and Dohme LLC, a subsidiary of Merck and Co., Inc, Rahway, NJ USA (Inst); Merck Sharp and Dohme LLC, a subsidiary of Merck and Co., Inc, Rahway, NJ USA (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Pfizer; Pfizer; Pfizer; Pfizer
 
Chandler H. Park
No Relationships to Disclose
 
Philippe Barthelemy
Honoraria - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; BMS; BMS; BMS; BMS; IPSEN; IPSEN; IPSEN; IPSEN; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; Merck KGaA; Merck KGaA; Merck KGaA; Merck KGaA; MSD; MSD; MSD; MSD; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; Seagen; Seagen; Seagen; Seagen
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; BMS; BMS; BMS; BMS; Eisai; Eisai; Eisai; Eisai; ipsen; ipsen; ipsen; ipsen; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; Merck KGaA; Merck KGaA; Merck KGaA; Merck KGaA; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Pfizer; Pfizer; Pfizer; Pfizer
Travel, Accommodations, Expenses - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; BMS; BMS; BMS; BMS; IPSEN; IPSEN; IPSEN; IPSEN; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; MSD; MSD; MSD; MSD; Pfizer; Pfizer; Pfizer; Pfizer
 
Manojkumar Bupathi
Honoraria - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Pfizer; Pfizer; Pfizer; Pfizer
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis; Exelixis; Exelixis; Exelixis
Speakers' Bureau - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis; Exelixis; Exelixis; Exelixis; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Pfizer; Pfizer; Pfizer; Pfizer
 
Daniel P. Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Consulting or Advisory Role - Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Amgen; Amgen; Amgen; Amgen; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bicycle Therapeutics; Bicycle Therapeutics; Bicycle Therapeutics; Bicycle Therapeutics; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Clovis Oncology; Clovis Oncology; Clovis Oncology; Clovis Oncology; Exelixis; Exelixis; Exelixis; Exelixis; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Incyte; Incyte; Incyte; Incyte; Ipsen; Ipsen; Ipsen; Ipsen; Janssen; Janssen; Janssen; Janssen; Lilly; Lilly; Lilly; Lilly; Mirati Therapeutics; Mirati Therapeutics; Mirati Therapeutics; Mirati Therapeutics; Monopteros Therapeutics; Monopteros Therapeutics; Monopteros Therapeutics; Monopteros Therapeutics; Pfizer; Pfizer; Pfizer; Pfizer; Pharmacyclics; Pharmacyclics; Pharmacyclics; Pharmacyclics; Regeneron; Regeneron; Regeneron; Regeneron; Roche; Roche; Roche; Roche; Seagen; Seagen; Seagen; Seagen; Urogen pharma; Urogen pharma; Urogen pharma; Urogen pharma
Research Funding - Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Agensys (Inst); Agensys (Inst); Agensys (Inst); Agensys (Inst); Astellas Medivation (Inst); Astellas Medivation (Inst); Astellas Medivation (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); BioXCel therapeutics (Inst); BioXCel therapeutics (Inst); BioXCel therapeutics (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Endocyte (Inst); Endocyte (Inst); Endocyte (Inst); Endocyte (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Innocrin Pharma (Inst); Innocrin Pharma (Inst); Innocrin Pharma (Inst); Innocrin Pharma (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); Medivation (Inst); Medivation (Inst); Medivation (Inst); Medivation (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Progenics (Inst); Progenics (Inst); Progenics (Inst); Progenics (Inst); Replimune (Inst); Replimune (Inst); Replimune (Inst); Replimune (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst)
Expert Testimony - Celgene; Celgene; Celgene; Celgene; sanofi; sanofi; sanofi; sanofi
 
Neeraj Agarwal
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AVEO; AVEO; AVEO; AVEO; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Calithera Biosciences; Calithera Biosciences; Calithera Biosciences; Calithera Biosciences; Eisai; Eisai; Eisai; Eisai; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Exelixis; Exelixis; Exelixis; Exelixis; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Genentech; Genentech; Genentech; Genentech; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Lilly; Lilly; Lilly; Lilly; Lilly; Lilly; Lilly; Lilly; Lilly; Lilly; Lilly; Lilly; Medivation/Astellas; Medivation/Astellas; Medivation/Astellas; Medivation/Astellas; MEI Pharma; MEI Pharma; MEI Pharma; MEI Pharma; Merck; Merck; Merck; Merck; Nektar; Nektar; Nektar; Nektar; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pharmacyclics; Pharmacyclics; Pharmacyclics; Pharmacyclics; Seagen; Seagen; Seagen; Seagen
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Arvinas (Inst); Arvinas (Inst); Arvinas (Inst); Arvinas (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Celldex (Inst); Celldex (Inst); Celldex (Inst); Celldex (Inst); crispr therapeutics (Inst); crispr therapeutics (Inst); crispr therapeutics (Inst); crispr therapeutics (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Sumati Gupta
Stock and Other Ownership Interests - Salarius Pharmaceuticals (I); Salarius Pharmaceuticals (I); Salarius Pharmaceuticals (I); Salarius Pharmaceuticals (I)
Research Funding - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Daiichi Sankyo/Lilly (Inst); Daiichi Sankyo/Lilly (Inst); Daiichi Sankyo/Lilly (Inst); Daiichi Sankyo/Lilly (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Hoosier Cancer Research Network (Inst); Hoosier Cancer Research Network (Inst); Hoosier Cancer Research Network (Inst); Hoosier Cancer Research Network (Inst); Immunocore (Inst); Immunocore (Inst); Immunocore (Inst); Immunocore (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); LSK BioPharma (Inst); LSK BioPharma (Inst); LSK BioPharma (Inst); LSK BioPharma (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Rexahn Pharmaceuticals (Inst); Rexahn Pharmaceuticals (Inst); Rexahn Pharmaceuticals (Inst); Rexahn Pharmaceuticals (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Viralytics (Inst); Viralytics (Inst); Viralytics (Inst); Viralytics (Inst)
Travel, Accommodations, Expenses - QED Therapeutics; QED Therapeutics; QED Therapeutics; QED Therapeutics
 
Aude Flechon
Honoraria - AAA HealthCare; AAA HealthCare; AAA HealthCare; AAA HealthCare; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; BMS; BMS; BMS; BMS; Ipsen; Ipsen; Ipsen; Ipsen; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; PFIZER; PFIZER; PFIZER; PFIZER; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Sanofi/Aventis; Sanofi/Aventis; Sanofi/Aventis; Sanofi/Aventis
Travel, Accommodations, Expenses - AAA HealthCare; AAA HealthCare; AAA HealthCare; AAA HealthCare; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; BMS; BMS; BMS; BMS; IPSEN; IPSEN; IPSEN; IPSEN; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Pfizer; Pfizer; Pfizer; Pfizer; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Sanofi/Aventis; Sanofi/Aventis; Sanofi/Aventis; Sanofi/Aventis
 
Chethan Ramamurthy
Consulting or Advisory Role - Seagen; Seagen; Seagen; Seagen
Speakers' Bureau - Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences
 
Nancy B. Davis
Consulting or Advisory Role - Janssen Biotech; Janssen Biotech; Janssen Biotech; Janssen Biotech
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Seattle Genetics/Astellas (Inst); Seattle Genetics/Astellas (Inst); Seattle Genetics/Astellas (Inst); Seattle Genetics/Astellas (Inst)
 
Alejandro Recio-Boiles
No Relationships to Disclose
 
Cora N. Sternberg
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb/Medarex; Bristol-Myers Squibb/Medarex; Bristol-Myers Squibb/Medarex; Bristol-Myers Squibb/Medarex; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Genzyme; Genzyme; Genzyme; Genzyme; Immunomedics; Immunomedics; Immunomedics; Immunomedics; IMPAC Medical Systems; IMPAC Medical Systems; IMPAC Medical Systems; IMPAC Medical Systems; Incyte; Incyte; Incyte; Incyte; Medscape; Medscape; Medscape; Medscape; Merck; Merck; Merck; Merck; MSD; MSD; MSD; MSD; Pfizer; Pfizer; Pfizer; Pfizer; Roche; Roche; Roche; Roche; UroToday; UroToday; UroToday; UroToday
 
Astha Bhatia
Employment - Bayer; Bayer; Bayer; Bayer; Bayer; Bayer; Bayer; Bayer; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation
Stock and Other Ownership Interests - Bayer; Bayer; Bayer; Bayer; Bayer; Bayer; Bayer; Bayer; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation
 
Cabilia Pichardo
Employment - Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences
 
Mitch Sierecki
Employment - Bayer; Bayer; Bayer; Bayer; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences
Stock and Other Ownership Interests - Bayer; Bayer; Bayer; Bayer; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences
 
Julia Tonelli
Stock and Other Ownership Interests - Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Myovant Sciences; Myovant Sciences; Myovant Sciences; Myovant Sciences
 
Huafeng Zhou
Employment - Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences
 
Scott T. Tagawa
Consulting or Advisory Role - 4D Pharma; 4D Pharma; 4D Pharma; 4D Pharma; Abbvie; Abbvie; Abbvie; Abbvie; AIkido Pharma; AIkido Pharma; AIkido Pharma; AIkido Pharma; Amgen; Amgen; Amgen; Amgen; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Bayer; Bayer; Bayer; Bayer; Blue Earth Diagnostics; Blue Earth Diagnostics; Blue Earth Diagnostics; Blue Earth Diagnostics; Clarity Pharmaceuticals; Clarity Pharmaceuticals; Clarity Pharmaceuticals; Clarity Pharmaceuticals; Clovis Oncology; Clovis Oncology; Clovis Oncology; Clovis Oncology; Convergent Therapeutics; Convergent Therapeutics; Convergent Therapeutics; Convergent Therapeutics; Dendreon; Dendreon; Dendreon; Dendreon; Endocyte; Endocyte; Endocyte; Endocyte; Genentech; Genentech; Genentech; Genentech; Genomic Health; Genomic Health; Genomic Health; Genomic Health; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Immunomedics; Immunomedics; Immunomedics; Immunomedics; Janssen; Janssen; Janssen; Janssen; Karyopharm Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Medivation; Medivation; Medivation; Medivation; Myovant Sciences; Myovant Sciences; Myovant Sciences; Myovant Sciences; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; POINT Biopharma; POINT Biopharma; POINT Biopharma; POINT Biopharma; QED Therapeutics; QED Therapeutics; QED Therapeutics; QED Therapeutics; Sanofi; Sanofi; Sanofi; Sanofi; Seagen; Seagen; Seagen; Seagen; Telix Pharmaceuticals; Telix Pharmaceuticals; Telix Pharmaceuticals; Telix Pharmaceuticals; Tolmar; Tolmar; Tolmar; Tolmar
Research Funding - Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AVEO (Inst); AVEO (Inst); AVEO (Inst); AVEO (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Dendreon (Inst); Dendreon (Inst); Dendreon (Inst); Dendreon (Inst); Endocyte (Inst); Endocyte (Inst); Endocyte (Inst); Endocyte (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Inovio Pharmaceuticals (Inst); Inovio Pharmaceuticals (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Karyopharm Therapeutics (Inst); Karyopharm Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Medivation (Inst); Medivation (Inst); Medivation (Inst); Medivation (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Millennium (Inst); Millennium (Inst); Millennium (Inst); Millennium (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); POINT Biopharma (Inst); POINT Biopharma (Inst); POINT Biopharma (Inst); POINT Biopharma (Inst); Progenics (Inst); Progenics (Inst); Progenics (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Rexahn Pharmaceuticals (Inst); Rexahn Pharmaceuticals (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Stem CentRx (Inst); Stem CentRx (Inst); Stem CentRx (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Patent Royalty from Immunomedics / Gilead; Patent Royalty from Immunomedics / Gilead; Patent Royalty from Immunomedics / Gilead; Patent Royalty from Immunomedics / Gilead
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Amgen; Immunomedics; Immunomedics; Immunomedics; Immunomedics; Sanofi; Sanofi; Sanofi; Sanofi
(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; ATLAB Pharma; ATLAB Pharma; ATLAB Pharma; Phosplatin Therapeutics; Phosplatin Therapeutics; Phosplatin Therapeutics; Phosplatin Therapeutics
 
Yohann Loriot
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Immunomedics; Immunomedics; Immunomedics; Immunomedics; Janssen; Janssen; Janssen; Janssen; Janssen (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Loxo/Lilly; Loxo/Lilly; Loxo/Lilly; Loxo/Lilly; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst); Pfizer/EMD Serono; Pfizer/EMD Serono; Pfizer/EMD Serono; Pfizer/EMD Serono; Roche; Roche; Roche; Roche; Seagen; Seagen; Seagen; Seagen; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Basilea (Inst); Basilea (Inst); Basilea (Inst); Basilea (Inst); BMS (Inst); BMS (Inst); BMS (Inst); BMS (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Merck KGaA (Inst); MSD Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Roche; Roche; Roche; Roche; Seagen; Seagen; Seagen; Seagen